Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 08, 2018 17:00 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Provides Corporate Update Highlighting Business Development and Clinical Pipeline Priorities

BEVERLY, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide a corporate update...
November 01, 2018 07:30 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Expands Brilacidin Patent Portfolio

BEVERLY, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that the U.S. Patent...
October 24, 2018 11:10 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Granted End-of-Phase 2 Meeting

BEVERLY, Mass., Oct. 24, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, announced today that the U.S. Food and Drug...
October 22, 2018 07:30 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Provides Update on Kevetrin Program; Bridging Toxicology Efforts Aimed at Developing an Oral p53 Anti-Cancer Drug Candidate

BEVERLY, Mass., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide a development update on...
October 12, 2018 12:00 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Brilacidin as a Novel Inhibitor of Phosphodiesterase 4 (PDE4) Supports its Potential to Treat Autoimmune and Inflammatory Diseases; Company Invited to Present at Upcoming Crohn’s & Colitis Foundation Conference

BEVERLY, Mass., Oct. 12, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide this update on...
October 09, 2018 07:00 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Secures Up to $10 Million in Additional Financing to Advance Clinical Pipeline

BEVERLY, Mass., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals, (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that it has secured new...
September 24, 2018 06:59 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Provides a Comparative Perspective on Brilacidin’s Potential to Unlock the Oral Mucositis Market: Pharma Industry Attacks Severe Pain and Suffering Due to Cancer Treatments

BEVERLY, Mass., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide a comparative...
September 20, 2018 09:15 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Provides Corporate Update Highlighting Upcoming Milestones and Events

BEVERLY, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to provide a corporate update on...
September 05, 2018 09:00 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals to Present Brilacidin for Inflammatory Bowel Disease at Inaugural “IBD Innovate 2018” Conference Hosted by the Crohn’s & Colitis Foundation

BEVERLY, Mass., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, announced today that the Company has been...
July 17, 2018 07:30 ET | Source: Innovation Pharmaceuticals, Inc.

Innovation Pharmaceuticals Signs Drug Product Manufacturing Contract with CoreRx to Formulate and Package Brilacidin for Oral Mucositis in Sachet Form

BEVERLY, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report the Company has signed a...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right